Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat and Pembrolizumab in Advanced Urothelial Carcinoma
NCT03854474Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2019
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of tazemetostat in urothelial carcinoma (UC), sponsored by National Cancer Institute. Primary endpoint: Recommended Phase 2 Dose at 21 days. Started Nov 2019; status: active, not recruiting.
02
Drugs
tazemetostat
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03854474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03854474.